Investors

Welcome on board!

Company overview

Pharnext is an advanced clinical-stage biopharmaceutical company committed to developing novel innovative therapeutics for orphan and common diseases with high unmet medical need.

Our proprietary R&D platform, PLEOTHERAPY™, systematically leverages genomic big data and AI to identify synergistic combinations of approved drugs or NCEs to generate new therapeutics with the potential to safely and effectively target and treat diseases.

˪ Disclosure of the total number of voting rights and shares comprising the share capital

Date

Number of shares comprising the share capital

Theoretical number of voting rights

December 31, 2020

19,404,296*

23,689,515

*Including 2,355,000 new shares issued from the equity line financing with Kepler Cheuvreux announced on November 19th 2019..

˪ Stock information

Stock Market

Euronext Growth Paris

Mnemo

ALPHA

Bloomberg

ALPHA/FR – Reuters: ALPHA.PA

ISIN Code


FR0011191287

Closing date


31 December

First day of trading


18 July 2016

Number of shares

19,404,296

Indices


EnterNext© PEA-PME 150,

Euronext Growth All-Share, Next Biotech, PEA

Liquidity contract


Kepler Cheuvreux

Eligible to PEA-PME (French fiscal advantage)

Share price


˪ Analysts coverage

The analysts listed on the right follow PHARNEXT. Any opinions, estimates or forecasts made by these analysts regarding PHARNEXT are individual and do not represent opinions, forecasts or predictions of PHARNEXT's management. PHARNEXT does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.

Kepler Cheuvreux : Damien Choplain - email
Gilbert Dupont : Guillaume Cuvillier - email
Edison Group : Nathaniel Calloway - email


Initiation of coverage report*
R&D Day Event report*

* These hyperlinks to a third party website are provided for information only and do not constitute an endorsement of any content provided therein.

General meeting (only available in French)
Contact
˪ For investors
Pharnext Headquarters
Pharnext

46 Rue Saint-Lazare

75009 Paris, France

+33 (0)1 41 09 22 30

inverstors@pharnext.com
International
Consilium Strategic Communications

Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison

pharnext@consilium-comms.com
France
Actifin France

Stéphane Ruiz

+33 (0)1 56 88 11 15

sruiz@actifin.fr
Contact
˪ For media
Pharnext Headquarters
Pharnext

46 Rue Saint-Lazare

75009 Paris

+33 (0)1 41 09 22 30

contact@pharnext.com
International
Consilium Strategic Communications

Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison

pharnext@consilium-comms.com
United States
RooneyPartners

Jeffrey Freedman

+1 646 432 0191

jfreedman@rooneyco.com
Next step
Home